McDermott advises Pierre Fabre on a strategic collaboration with Atara Biotherapeutics to commercialize Tabelecleucel (Tab-cel®) - McDermott Will & Emery

McDermott advises Pierre Fabre on a strategic collaboration with Atara Biotherapeutics to commercialize Tabelecleucel (Tab-cel®)

Overview


McDermott Will & Emery has advised Pierre Fabre on a strategic collaboration with Atara Biotherapeutics to commercialize Tab-cel® in Europe, the Middle East, Africa and other selected emerging markets for Epstein-Barr virus (EBV) positive cancers.

The McDermott team that advised Pierre Fabre included Emmanuelle Trombe, Anne-France Moreau (partners) and Edouard Becker (associate).

About McDermott


McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.